Irreversible hearing loss affects hundreds of millions worldwide, often caused by damage to cochlear hair cells that cannot regenerate in humans. New research into the molecular pathways of hair cell ...

The FDA has granted accelerated approval to lunsotogene parvec-cwha (Otarmeni), an adeno-associated virus (AAV) vector–based ...

The kinocilium of vestibular hair cells is a unique organelle with molecular features of primary and motile cilia and may serve as an active, force-generating element within the hair bundle.

The FDA has granted an accelerated approval for Otarmeni (lunsotogene parvec-cwha), the first gene therapy to treat patients ...

An experimental gene therapy for a rare form of genetic deafness has successfully restored hearing in children and adults, ...

The mammalian cochlea is an extraordinary biomechanical system whose capacity for sensitivity and frequency discrimination hinges on intricate interactions between its passive structures and active ...

When the parents of a toddler born profoundly deaf learned their child carried mutations in both copies of the OTOF gene, a ...

Research team awarded five-year, $3.2 million grant from National Institute on Deafness and Other Communication Disorders AHL is among the most common health conditions affecting older adults, ...

The FDA has granted accelerated approval to Otarmeni™ (lunsotogene parvec-cwha), the first gene therapy for pediatric and adult patients with OTOF-related sensorineural hearing loss.

The treatment, the first of its kind, was approved by the Food and Drug Administration on Thursday. “Our baby was born deaf, ...

A new gene therapy tested in China has improved the hearing of 38 people who were born deaf due to mutations in a gene called ...